AB0911 The relationship between neuropathic pain and disease activity, sleep, fatigue, quality of life in patients with psoriatic arthritis
Authors: C. Unal, F. Ulutatar, M.T. Duruoz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Neuropathic pain (NP) is composed of several abnormal sensations, including burning, prickling hyperalgesia and allodynia. NP is a common problem in rheumatic diseases such as rheumatoid arthritis and ankylosing spondylitis due to inflammatory processes. Previous studies showed that NP in other rheumatic diseases had a negative influence on sleep and quality of life.<sup>1, 2</sup> <h3>Objectives</h3> To examine the relation of neuropathic pain symptoms in Psoriatic Arthritis (PsA) with demographic, clinical and functional parameters. <h3>Methods</h3> PsA patients according to CASPAR criteria were recruited into the study. Demographic and clinical parameters were noted. PainDETECT measurement tool was used for evaluation of NP. Physical examination such as manual muscle testing and sensory examination for hyperalgesia and allodynia was performed (pinprick and light touch test). Disease Activity Score-28 (DAS-28) was noted for disease activity. Associations of NP with quality of life, sleep and fatigue were analysed by filling out Psoriatic Quality of Life (PsAQoL), Pittsburgh Sleep Quality Index (PSQI), Multidimensional Assessment of Fatigue (MAF). PainDETECT scores were categorised as no NP (&lt;12 points), ambiguous NP (13–18 points), probable NP (≥19 points). Group analysis was performed with Independent-Samples Kruskal-Wallis test. Spearman correlation coefficient (rho) was used for correlations between functional parameters. p&lt;0.05 was accepted as significant. <h3>Results</h3> Forty eight PsA patients (31 female, 17 male) with a mean age 50.4 years (SD:10.0) and mean disease duration 92.2 months (SD: 90.2) were recruited into the study. The number of patients with ambiguous NP was 6 patients (4 female, 2 male) and probable NP was 12 patients (10 female, 2 male). The mean scores of PSQI, PsAQoL and MAF were significantly higher in patients with NP (p&lt;0.05). There was no difference in mean scores of DAS-28 and disease duration among groups. The correlations between PainDETECT and other functional parameters were found moderate-strong as PSQI (rho=0.43, p=0.002), MAF (rho=0.44, p=0.002), PsAQoL (rho=0.66, p=0.0005). Also, the probability of NP existence increased with the age (rho=0.40, p=0.01). There was no significant correlation between and clinical parameters such as disease duration and DAS-28 (p&gt;0.05). <h3>Conclusions</h3> These findings suggest that a substantial number of PsA patients suffering from NP. The neuropathic pain symptoms are found to be associated with worse self-reported quality of life and sleep disturbances. It is important to consider the existence of NP in the assessment and treatment process of PsA. <h3>References</h3> [1] O'Connor AB, et al. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009; 27:95–112. [2] Argoff CE, et al. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007; 23:15–22. <h3>Disclosure of Interest</h3> None declared